1 active not recruiting, 1 completed, 1 recruiting, 1 terminated. 4 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow QR-110: new trials by email Literature Review of QR-110 trials Research Report on QR-110
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) sepofarsen, Placebo IVT - Leber Congenital Amaurosis 10, Blindness | Phase 3 | Recruiting | Laboratoires Thea | 32 | 2025-06-04 | 2026-10-21 |
| An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. sepofarsen - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Unknown | ProQR Therapeutics | 15 | 2021-03-23 | 2022-03-25 |
| Extension Study to Study PQ-110-001 (NCT03140969) QR-110 - Leber Congenital Amaurosis 10, Blindness | Phase 1 / Phase 2 | Terminated | Laboratoires Thea | 9 | 2019-05-13 | 2024-10-15 |
| A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) sepofarsen, Sham - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Active not recruiting | ProQR Therapeutics | 36 | 2019-04-04 | 2022-03-17 |
| Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene QR-110 - Leber's Congenital Amaurosis | Phase 1 / Phase 2 | Completed | Laboratoires Thea | 11 | 2017-10-16 | 2024-10-15 |
Meckel Syndrome, Type 4 (5) · Blindness (4) · Eye Abnormalities (4) · Eye Diseases (4) · Leber Congenital Amaurosis (4) · Leber Congenital Amaurosis 10 (4) · Neurologic Manifestations (4) · Optic Atrophy, Hereditary, Leber (4) · Retinal Diseases (4) · Sensation Disorders (4) · Vision Disorders (4) · Eye Diseases, Hereditary (3) · Retinal Degeneration (1) · Retinal Dystrophies (1)
Laboratoires Thea (3) · ProQR Therapeutics (2)
Belgium (5) · United States (4) · Brazil (3) · Canada (3) · Germany (3) · Netherlands (3) · United Kingdom (3) · France (2) · Italy (2) · Australia (1) · Spain (1)
PMID 30559420, PMID 31215818, PMID 33795869, PMID 35379979
2018 (2), 2017 (1)